From upfront discounts to rebate-based pricing—QuicksortRx gives you the tools to stay compliant, plan, and act quickly in a shifting regulatory environment.
Request your personalized analysis.
HRSA has approved a revised 340B Rebate Model Pilot Program, scheduled to begin January 1, 2027, though it has been challenged in court and details could change.
For covered entities, this would mean paying full WAC upfront—then waiting for rebate checks later. That delay could put significant cash flow pressures on health systems.
We built a tool to help our customers navigate the change.
Equip yourself to confidently advise finance leaders with insights at your fingertips.
Your pricing data showing WAC spend for every NDC in the pilot
Assess impact for 2026 and additional 2027 projections
Estimated rebate lag effects on cash flow
Detailed net exposure breakdown by drug and category
The 340B Rebate Pilot Report is just the start. We don’t wait for policy to finalize—we build so you can act now. We’ll keep tracking HRSA and the court case, and we’re exploring real-time rebate reconciliation, increased price transparency, and future tools for inpatient and infusion workflows.